|Use of Lu-177 PSMA in prostate cancer treatment|
GUWAHATI, Feb 25 - City-based nuclear medicine and PETCT centre Nucleomed has got clearance from the Atomic Energy Regulatory Board, Govt of India to use Lutetium 177 PSMA and Lu-177 DOTATOC for treatment of advance prostate cancer and neuroendocrine tumours after few months of scrutiny, said a press release.
Senior medical oncologist Dr Cidananda Bhuyan, senior urologist Dr Sujit Saikia and prominent gastroenterologist Dr Kamal Chetri said this beta radiation therapy for the first time in Assam will be of great help in their field of treatment.
Dr BJ Saikia of Dr B Borooah Cancer Institute, said the new facility could start a new era in molecular imaging and therapy in Assam and the North East.
In men who fail initial therapy of curative intent (radical prostatectomy or primary radiotherapy), treatment options include androgen deprivation therapy followed by chemotherapy if the disease progresses.
However, conventional chemotherapy responses are often transient, leaving many men with symptomatic metastatic cancer and few treatment options.
In such situations targeted radionuclide therapy with 177 Lutetium PSMA is the only viable therapeutic option in men with metastatic advance prostate cancer.
Likewise, 177 Lutetium DOTATOC has shown better results in advanced gastroenteropancreatic and bronchial neuroendocrine tumours.
Meanwhile, sending their first patients for advance prostate cancer therapy by Lu-177 PSMA to Nucleomed, the authorities of NE Cancer Hospital said now all cancer therapies or diagnosis are available in Assam.